ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference

Company Overview - ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2] - The company currently manufactures and markets three FDA-approved plasma-derived biologics: BIVIGAM® for primary humoral immunodeficiency, ASCENIV™ for primary immunodeficiency, and NABI-HB® for enhanced immunity against hepatitis B [2] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and also functions as an FDA-approved source plasma collector through its subsidiary, ADMA BioCenters [2] Upcoming Events - Adam Grossman, President and CEO of ADMA, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on September 17, 2024, at 3:05 p.m. ET [1] - A live audio webcast of the event will be available on the company's investor website, with an archived version accessible approximately two hours post-event [1]